Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease

Neuroendocrinology Letters

Volumn 19, Issue 3, 1998, Pages 111-115

  Brusco, Luis I ^a   Marquez, Miguel ^a   Cardinali, Daniel P ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Aging; Alzheimer's disease; Cognitive impairment; Melatonin's antioxidant properties; Sleep disorders

Indexed keywords

GELATIN; MELATONIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIORAL SCIENCE; BRAIN ATROPHY; CHRONOBIOLOGY; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; DISEASE COURSE; EVALUATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; NEUROPSYCHOLOGY; SLEEP DISORDER; TEMPORAL CORTEX;

EID: 0032429075     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Auer S, Reisber B (1997) The GDS/FAST staging system. Int Psychogeriatr 9(Suppl 1): 167-171
2. Blessed G, Tomlinson BE, Roth M (1988) Blessed-Roth dementia scale (DS). Psychopharmacol Bull 24: 689-692
3. Bozner P, Grishko V, Ledoux SP, Wilson GL, Chyan YC, Pappolla MA (1997) The amyloid β-protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol 56: 1356-1362
4. Brusco Ll, Márquez M, Cardinali DP (1998) Monozygotic twins with Alzheimer's disease treated with melatonin. Case report. J Pineal Res, in press
5. Daniels WM, Van Rensburg SJ, Van Zyl JM, Taljaard JJ (1998) Melatonin prevents β amyloid, induced lipid peroxidation. J Pineal Res 24: 78-82
6. Fainstein I, Bonetto AJ, Brusco Ll, Cardinali DP (1997) Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Current Ther Res 58: 990-1000
7. Jost BC, Grossberg GT (1996) The evolution of the psychiatric symptoms in Alzheimer's disease: A natural history study. J Am Geriatr Soc 44: 1078-1081
8. Kaplan HI, Sadock BJ, Grebb JA (1994) Synopsis of Psychiatry, 7th edn. Williams & Wilkins, Baltimore, pp. 705-707
9. Katzman R, Kawas C (1994) The epidemiology of dementia and Alzheimer disease. In: Terry RD, Katzman R, Bick KL (eds.) Alzheimer Disease. Raven, New York, pp. 105-122
10. Kotler M, Rodríguez C, Sainz RM, Antolin I, Menéndez Pelaez A (1998) melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 24: 83-89
11. Mattis S (1988) Dementia Rating Scale Professional Manual. Psychological Assessment Resources, Odess, FL
12. McGaffigan S, Bliwise DL (1997) The treatment of sundowning: A selective review of pharmacological and nonpharmacological studies. Drugs & Aging 10: 10-17
13. Mohs RC, Cohen L (1988) Alzheimer's disease assessment scale (ADAS). Psychopharmacol Bull 24: 627-628
14. Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J (1998) Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem 273: 7185-7188
15. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter RJ, Efthimiopoulos S, Robakis NK (1997) Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 17: 1683-1690
16. Reiter RJ, Tang L, Garcia JJ, Muñoz Hoyos A (1997) Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci 60: 225-271
17. Rogers SL, Friedhoff LT (1998) Long-term efficacy and safety of donazepil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8: 67-75
18. Song W, Lahiri K (1997) Melatonin alters the metabolism of the β-amyloid precursor protein in the neuroendocrine cell line PC 12. J Mol Neurosci 9: 75-92